10x Genomics, Inc. (Nasdaq: TXG), a pioneering company in single cell and spatial biology, has announced the commercial release of its Xenium multi-modal cell segmentation kit alongside a newly optimized Xenium gene panel for immuno-oncology applications. These advancements mark a significant extension of the Xenium platform’s capabilities, solidifying its position as a leading tool for in situ analysis within the field.

Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics, emphasized the company’s commitment to excellence and responsiveness to customer feedback. “We built Xenium to be the best performing platform for in situ analysis, not only at launch, but for the long term,” Schnall-Levin stated. The introduction of these products underscores 10x Genomics’ dedication to continual innovation, with plans to further expand the Xenium assay portfolio throughout the year.

The Xenium In Situ Cell Segmentation Kit represents a leap forward in accurately determining cell boundaries. It employs a sophisticated stain and algorithmic technique, underpinned by custom-trained machine learning models, to ensure precise transcript-to-cell assignments. This new solution offers seamless integration into existing workflows, validated across diverse tissue types in both human and mouse samples.

The Xenium Immuno-Oncology Panel provides a comprehensive toolset for delving into the complex interactions within the tumor microenvironment. As the first application-focused panel on the Xenium platform, it offers extensive detection capabilities for a wide array of immune cell types and states. This customizable panel, optimized for a variety of cancer types, is designed to unlock new insights into tumor biology and the immune landscape, paving the way for the development of targeted therapies.

Quan Nguyen, Group Leader at the University of Queensland, praised the Xenium platform’s capabilities, noting, “We found that the experimental data obtained from Xenium membrane staining consistently yields the most accurate segmentation results.” This endorsement highlights the platform’s potential to significantly enhance the understanding of cell types and interactions, a crucial factor in advancing cellular biology research.

With the establishment of Gemini Studios across its global Cloud AI Innovation hubs and the creation of dedicated Google Cloud delivery centers, 10x Genomics is poised to lead the charge in the integration of generative AI within the field of cellular biology. This strategic expansion underscores the company’s vision of harnessing AI to unlock new possibilities in genetic research and therapy development.

The collaboration between 10x Genomics and its partners is set to redefine the landscape of single cell and spatial biology, offering researchers unprecedented tools to explore the intricacies of cellular function and disease pathology.

  10x Genomics, AI in biology, cell segmentation kit, gene panel, immuno-oncology, single cell, spatial biology, Xenium